Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Parallel Group, Double Blind, Multiple Dose, Placebo Controlled Study to Assess the Efficacy and Safety of MNK-1411 in Male Participants 4 to 8 Years of Age With Duchenne Muscular Dystrophy

NCT03400852 is registered in ClinicalTrials.gov with Mallinckrodt ARD LLC as lead sponsor.

NCT NCT03400852
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03400852 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Parallel Group, Double Blind, Multiple Dose, Placebo Controlled Study to Assess the Efficacy and Safety of MNK-1411 in Male Participants 4 to 8 Years of Age With Duchenne Muscular Dystrophy
Lead sponsor
Mallinckrodt ARD LLC
Phase
Phase 2
Overall status
Terminated
Start date
July 27, 2018
Completion date
February 25, 2020
Enrollment
44 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

muscular dystrophy, duchenne